In this newsletter…

  • Updates on Zika virus 
  • Genetics Corner 
  • Meet our perinatologist

Zika Virus Testing Updates 

On July 24, 2017, the Center for Disease Control (CDC) yet again revised its guidelines for the caring of pregnant women with possible Zika virus infection.

Recommendations that did not change include: 

  • Pregnant women should not travel to areas with risk of Zika infection. 
  • If a pregnant woman must travel to one of these at risk areas, she should strictly follow steps to avoid mosquito bites and prevent sexual transmission of Zika during and after the trip. 
  • Pregnant women with Zika symptoms and with possible Zika exposure should be tested for Zika virus infection.
  • Pregnant women with no Zika symptoms but who have ongoing Zika exposure should be offered Zika testing. 
  • Prenatal ultrasonography to evaluate for fetal abnormalities consistent with congenital Zika virus syndrome is recommended for all pregnant women with possible exposure to Zika virus.

Recommendations that were revised include: 

  • Testing is no longer routinely recommended for pregnant women with no Zika symptoms who have recent possible exposure to Zika but no ongoing exposure.
  • Testing is recommended if a Zika compatible abnormality is noted in the fetus on ultrasound.

The New Jersey Department of Health has endorsed the above recommendations. 

Internet Based Zika Resources 

Genetics Corner 

Fetal Aneuploidy Screening 

Our practice recently revised our clinical management guidelines regarding screening for fetal aneuploidy. These guidelines were updated in May 2016 (Practice Bulletin #163) by the ACOG Committee on Genetics  and the Society for Maternal‐Fetal Medicine. In the revised bulletin, it is recommended that a woman with a normal screen not be offered additional aneuploidy screening as it increases the chance of a  false positive result.  

All pregnant women, regardless of age, will continue to receive pre‐test counseling at  New Jersey Perinatal Associates. Prior to reaching any decisions about testing, they  will be counseled by either a perinatologist or a genetic counselor about prenatal screening and diagnostic options for fetal aneuploidy. 

While NIPT (non‐invasive prenatal testing) may appear to be “the easy choice” for  prenatal screening because of its ease of use and increased detection, it is important  to acknowledge that it may not be suitable for all patients.  For example, women with a high BMI or anticoagulant use, have a higher incidence of a non‐reportable  result, which is an indication for invasive prenatal diagnosis. Also, a co‐twin demise that occurred within 8 weeks or more can increase the false positive rate.  In these cases, first trimester screening may be more appropriate. Furthermore, NIPT may have a considerable out‐of‐pocket expense for some patients (especially when it is  applied to a high‐deductible insurance policy). 

In accordance with these guidelines, only one form of prenatal screening (i.e., first  trimester screening, maternal quadruple screen or non‐invasive prenatal test) will be  offered. First trimester biochemistry will not be offered to patients who opt for or who have had NIPT.  For this reason, communication with our office about a patient’s  NIPT results (if ordered) is critical.  It is appropriate to offer NIPT to a patient whose  risk of aneuploidy is increased by traditional screening methods (i.e., first trimester  screening, maternal serum screening). However, it is important to also note that this approach may delay a definitive diagnosis and may cause some affected pregnancies  to escape detection.

Ultrasound to measure the nuchal translucency, as well as screen for certain birth  defects, in the first trimester is still recommended and will be performed between 11  and 14 weeks’ gestation at NJPA. As always, same day genetic counseling and diagnostic testing will be made available to those with significant ultrasound findings,  whenever possible. 

 

Meet Our Perinatologist 

Richard Miller, MD 

 

Dr.  Miller  graduated  from Georgetown  University School of Medicine and completed  his residency in Obstetrics and Gynecology at  the National Naval Medical Center in Bethesda, Maryland. He completed his fellowship training  in maternal‐fetal medicine at the University of North Carolina at Chapel Hill in 1991. Before moving to New Jersey, he spent four  years as Director of the Division of Maternal-Fetal Medicine at the National Naval Medical Center and was a member of the faculty at the  Uniformed Services University of the Health Sciences and the National Institutes of Health. Dr. Miller’s research interests include outcome-based analysis of prenatal care and prenatal  diagnosis. 

To download this newsletter, please click here.